Literature DB >> 20626561

The RGD-containing peptide fragment of osteopontin protects tyrosine hydroxylase positive cells against toxic insult in primary ventral mesencephalic cultures and in the rat substantia nigra.

Joanna Iczkiewicz1, Lauren Broom, Jonathan D Cooper, Andrew Ming Sham Wong, Sarah Rose, Peter Jenner.   

Abstract

We have previously shown that the multi-functional phosphoprotein osteopontin (OPN) is present in the substantia nigra (SN) and that its mRNA and protein expression are up-regulated following toxic insult. We now report the effects of the arginine-glycine-aspartic acid (RGD)-containing peptide fragment of OPN and OPN inactivation on the survival of tyrosine hydroxylase (TH) positive neurones in primary rat ventral mesencephalic (VM) cultures and in SN in the rat. Treatment of VM cultures with the fragment of OPN containing the RGD integrin binding domain did not decrease TH positive cell number, but instead the peptide fragment protected against cell loss induced by both MPP(+) and lipopolysaccharide (LPS). Incorporation of an OPN antibody into VM cultures caused a concentration-dependent loss of TH positive neurones. The OPN antibody also exacerbated MPP(+) - and LPS-induced cell loss at all concentrations tested. In the rat, administration of the RGD-containing peptide fragment of OPN protected TH positive neurones against a mechanically-induced lesion and against 6-hydroxydopamine- and LPS-induced cell loss. The protection against 6-hydroxydopamine toxicity was confirmed in a separate study using stereological analysis. By contrast, stereotaxic injection of the OPN antibody into the SN resulted in a loss of TH positive cells. These results suggest that OPN may be necessary for the survival of TH positive cells in SN but through the RGD-containing peptide fragment may also have neuroprotective properties relevant to Parkinson's disease.
© 2010 The Authors. Journal Compilation © 2010 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626561     DOI: 10.1111/j.1471-4159.2010.06896.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

1.  Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease.

Authors:  Matthew J Betts; Michael J O'Neill; Susan Duty
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

2.  Intranasal Delivery of RGD Motif-Containing Osteopontin Icosamer Confers Neuroprotection in the Postischemic Brain via αvβ3 Integrin Binding.

Authors:  Yin-Chuan Jin; Hahnbie Lee; Seung-Woo Kim; Il-Doo Kim; Hye-Kyung Lee; Yunjin Lee; Pyung-Lim Han; Ja-Kyeong Lee
Journal:  Mol Neurobiol       Date:  2015-10-19       Impact factor: 5.590

3.  Osteocalcin- and osteopontin-containing neurons in the rat hind brain.

Authors:  Toshihiko Suzuki; Tadasu Sato; Hiroyuki Ichikawa
Journal:  Cell Mol Neurobiol       Date:  2012-05-03       Impact factor: 5.046

Review 4.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  The endotoxin-induced neuroinflammation model of Parkinson's disease.

Authors:  Kemal Ugur Tufekci; Sermin Genc; Kursad Genc
Journal:  Parkinsons Dis       Date:  2011-01-18

6.  Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.

Authors:  Marica Carbone; Susan Duty; Marcus Rattray
Journal:  BMC Neurosci       Date:  2012-04-05       Impact factor: 3.288

7.  Osteopontin expression in the brain triggers localized inflammation and cell death when immune cells are activated by pertussis toxin.

Authors:  Maria Cecilia Garibaldi Marcondes; Ryan Ojakian; Nikki Bortell; Claudia Flynn; Bruno Conti; Howard S Fox
Journal:  Mediators Inflamm       Date:  2014-11-24       Impact factor: 4.711

8.  Osteopontin Peptide Icosamer Containing RGD and SLAYGLR Motifs Enhances the Motility and Phagocytic Activity of Microglia.

Authors:  Il-Doo Kim; Hahnbie Lee; Yin-Chuan Jin; Ja-Kyeong Lee
Journal:  Exp Neurobiol       Date:  2017-12-11       Impact factor: 3.261

9.  Licochalcone A Prevents the Loss of Dopaminergic Neurons by Inhibiting Microglial Activation in Lipopolysaccharide (LPS)-Induced Parkinson's Disease Models.

Authors:  Bingxu Huang; Juxiong Liu; Chen Ju; Dongxue Yang; Guangxin Chen; Shiyao Xu; Yalong Zeng; Xuan Yan; Wei Wang; Dianfeng Liu; Shoupeng Fu
Journal:  Int J Mol Sci       Date:  2017-09-22       Impact factor: 5.923

Review 10.  Bone-Derived Modulators That Regulate Brain Function: Emerging Therapeutic Targets for Neurological Disorders.

Authors:  Hongzhen Chen; Dewei Shang; Yuguan Wen; Chao Liang
Journal:  Front Cell Dev Biol       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.